ea0025pl8 | Clinical Endocrinology Trust Visiting Professor Lecture | SFEBES2011
Fagin James
Our understanding of the genetic abnormalities associated with thyroid cancers has grown significantly over the past decade. Thus, papillary thyroid cancers (PTC) have non-overlapping activating mutations genes encoding the growth factor receptors RET or NTRK, the three isoforms of RAS, or of BRAF, which altogether are found in ~70% of cases. In addition, mutations of effectors in the phosphoinositol-3-kinase (PI3K) pathway are present at various stages of the disease, but in ...